Table 1 Univariate (Kaplan–Meier) and multivariate (Cox proportional hazard regression) analysis of event-free survival in 143 neuroblastoma patients

From: MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome

  

Univariate a

Multivariate b

     

Entered

Stepwise c

Variable

n

HR

95% CI

EFS P

HR

95% CI

EFS P

HR c

95% CI

EFS P

INSS

 Stage 4

72

6.59

3.3–12.9

<0.0001

3.10

1.3–7.3

0.0095

5.25

2.4–11.4

<0.0001

 Stage 1, 2, 3, 4S

71

1

  

1

  

1

  

 Stage 3, 4

104

22.5

11.7–43.1

<0.0001

6.49

0.8–52.6

0.0812

—

—

—

 Stage 1, 2, 4S

39

1

  

1

     

Age

 ⩾1 year

123

2.42

1.1–5.4

0.0331

2.69

0.6–11.7

0.1815

—

—

—

 <1 year

20

1

  

1

     

MYCN

 Amplified

33

3.7

1.7–8.1

0.0011

1.80

0.9–3.8

0.1187

—

—

—

 Non amplified

110

1

  

1

     

11q

          

 Deletion

50

2.25

1.3–4.4

0.0154

1.28

0.6–2.7

0.5132

—

—

—

 No deletion

93

1

  

1

     

MiR-204

 Low expression

72

4.89

2.5–9.3

<0.0001

2.61

1.1–5.8

0.0206

3.13

1.69–7.9

0.0011

 High expression

71

1

  

1

  

1

  
  1. Abbreviations: EFS=event-free survival; HR=hazard ratio; INSS=international neuroblastoma staging system; 95% CI=95% confidence interval.
  2. aKaplan–Meier P-values for EFS= log-rank.
  3. bVariables entered in Cox proportional hazard model: mIR-204 expression (low expression < median, high expression > median), INSS (stage 3 and 4, stages 1, 2, 4S and stage 4, stages 1, 2, 3, 4S), age (⩾1 year, <1 year), MYCN amplified (yes, no) and chromosome 11q deleted (yes, no).
  4. cThe variables age, MYCN status, 11q status and INSS stage 3, 4 vs stage 1, 2, 4S were found not to significantly contribute to the prediction of EFS time and were excluded in the stepwise Cox multivariate model.
Back to article page